Effects of Trimetazidine combined with Metoprolol in treatment of patients with coronary heart disease complicated with heart failure
Objective:To observe effects of Trimetazidine combined with Metoprolol in treatment of patients with coronary heart disease complicated with heart failure.Methods:The clinical data of 60 patients with coronary heart disease and heart failure admitted to this hospital from May 2020 to March 2023 were retrospectively analyzed.According to different treatment methods,they were divided into control group and observation group,30 cases in each group.Both groups received routine treatment.On this basis,the control group was treated with Metoprolol,while the observation group was treated with Trimetazidine on the basis of that of the control group.Both groups were treated for 2 months.The clinical efficacy,the levels of cardiac function indexes[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)],myocardial fibrosis indexes[type III procollagen amino terminal peptide(PIIINP),type I procollagen carboxy terminal peptide(PICP),type I collagen cross-linked carboxyl terminal peptide(ICTP)]and oxidative stress indexes[malondialdehyde(MDA),superoxide dismutase(SOD)],vascular endothelial function indexes[endothelin-1(ET-1),vascular endothelial growth factor(VEGF)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 93.33%(28/30),which was higher than 66.67%(20/30)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of LVEDD and LVESD in the observation group were lower than those in the control group,the level of LVEF was higher than that in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of PIIINP,PICP and ICTP in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the MDA level in the observation group was lower than that in the control group,the SOD level was higher than that in the control group,and the differences were statistically significant(P<0.05).After the treatment,the level of ET-1 in the observation group was lower than that in the control group,the level of VEGF was higher than that in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Trimetazidine combined with Metoprolol can improve the total effective rate and the levels of cardiac function indexes,oxidative stress indexes and vascular endothelial function indexes in the patients with coronary heart disease complicated with heart failure.Moreover,it is superior to single Metoprolol treatment.
NETL
NSTL
万方数据
